CoChat
Sign Up
Cited by 183Attention Deficit Hyperactivity DisorderBehavioral and Psychological StudiesDevelopmental and Educational Neuropsychology

The DOI matches its Crossref record; 190 of the 191 references it cites were found in a registry or an index.

Non?stimulant medications in the treatment of ADHD

Banaschewski, T., Roessner, V., Dittmann, R.W., Janardhanan Santosh, P., Rothenberger, A.·2004·European Child & Adolescent Psychiatry
DOI 10.1007/s00787-004-1010-x
Open this paper in CoChat — free account

Abstract

Background Stimulants are the first-line medication in the psychopharmacological treatment of attention-deficit hyperactivity disorder (ADHD). However, 10 to 30% of all children and adults with ADHD either do not respond to or do not tolerate treatment with stimulants. Objective To describe alternative treatment approaches with various non-stimulant agents, especially atomoxetine. Method General review of empirically based literature concerning efficacy and safety of the substances. Results A large and still increasing body of data supports the usefulness of atomoxetine, a once daily dosing, and new selective noradrenalin reuptake inhibitor, with few side effects. Atomoxetine has been licensed in the US for use in ADHD across the lifespan, and is currently under consideration in Europe. Other non-stimulant substances, such as tricyclic antidepressants (TCAs) and alpha-2-adrenergic agonists, which are used to treat ADHD, are also reviewed. TCAs have been well studied and shown to be efficacious in the treatment of ADHD, but are limited by side effects. The number of studies documenting the efficacy of alpha-2-adrenergic agonists is still limited. Some experimental studies support a potential role of cholinergic drugs such as acetylcholinesterase inhibitors (tacrine, donepezil) as well as novel nicotinic analogues (ABT-418). Conclusion Non-stimulant agents have been shown to be effective in treatment of ADHD. Especially, atomoxetine seems promising and newline drugs are in deve…

Overview

Integrity signals

Registry

Crossref · 10.1007/s00787-004-1010-x

Cites

190 of 190 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 191 references

Cited by

Sorted by citations

Items 101–183 of 183

Related

See all

Metadata

Authors
Banaschewski, T., Roessner, V., Dittmann, R. W., Janardhanan Santosh, P., & Rothenberger, A.
Affiliations
  • University of Göttingen (DE)
  • Universität Hamburg (DE)
ORCID
Venue
European Child & Adolescent Psychiatry
Publisher
Springer Science and Business Media LLC
Published
2004-07
Volume
13
Issue
S1
Pages
I102-16
ISSN
  • 1018-8827 (ISSN-L)
  • 1435-165X
DOI
10.1007/s00787-004-1010-x
OpenAlex
W1999326093
Cited by
183
References
191
Citations by year
2026: 1 · 2025: 7 · 2024: 4 · 2023: 9 · 2022: 8 · 2021: 4 · 2020: 4 · 2019: 8 · 2018: 6 · 2017: 7 · 2016: 13 · 2015: 6 · 2014: 9 · 2013: 6 · 2012: 12
FWCI
6.18
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • European Child & Adolescent Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • GRO (submittedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
  • Social Sciences › Psychology › Neuropsychology and Physiological Psychology › Developmental and Educational Neuropsychology
Keywords
attention deficit hyperactivity disorder, non-stimulant medication, atomoxetine, norepinephrine reuptake inhibitors, tricyclic antidepressants, alpha-2 adrenergic agonists, acetylcholinesterase inhibitors, nicotinic agonists, drug safety and efficacy
MeSH terms
Atomoxetine Hydrochloride, Antidepressive Agents, Tricyclic, Attention Deficit Disorder with Hyperactivity, Child, Drug Interactions, Drug Tolerance, Humans, Norepinephrine, Propylamines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review